Morbidity and Mortality Weekly Report: Recommendations and Reports, December 17, 2021 / Vol. 70 / No. RR-6

Details

• Alternative Title:
  Dengue Vaccine : Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Paz-Bailey, Gabriela ; Adams, Laura ; Wong, Joshua M. ; Poehling, Katherine A. ; Chen, Wilbur H. ; McNally, Veronica ; Atmar, Robert L. ; Waterman, Stephen H.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. ; Wake Forest School of Medicine. ; University of Maryland School of Medicine. ; Michigan State University. ; Baylor College of Medicine.
• Description:
  Dengue is a vector borne infectious disease caused by dengue viruses (DENVs), which are predominantly transmitted by Aedes aegypti and Aedes albopictus mosquitos. Dengue is caused by four closely related viruses (DENV-1-4), and a person can be infected with each serotype for a total of four infections during their lifetime. Areas where dengue is endemic in the United States and its territories and freely associated states include Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. Dengvaxia was licensed by the Food and Drug Administration for use among children and adolescents aged 9-16 years (referred to in this report as children). ACIP recommends vaccination with Dengvaxia for children aged 9-16 having evidence of a previous dengue infection and living in areas where dengue is endemic. Evidence of previous dengue infection, such as detection of anti-DENV immunoglobulin G with a highly specific serodiagnostic test, will be required for eligible children before vaccination.
  
  Suggested citation for this article: Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16.
  
  rr7006a1.htm?s_cid=rr7006a1_w
  
  rr7006a1-H.pdf
  
  
• Subjects:
  Advisory Committees Dengue / Prevention & Control Dengue Vaccines
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2021; v. 70, no. 6
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print) ; 1545-8601 (digital)
• Document Type:
  Journal Issue
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  20 pdf pages
• Volume:
  70
• Issue:
  6
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:205f06f55609c06d7a9aca1880a511cc391fedeb0fb1d5df857ce1b6f3db845a344da1b127ddcdd0a2fad69e4e1907e6b584ca94e065097e53d2865e19204c39
• Download URL:
  https://stacks.cdc.gov/view/cdc/113740/cdc_113740_DS1.pdf
• File Type:
  [PDF - 381.11 KB ]